- Home
- MPU vs AEON Comparison
MPU vs AEON Comparison
Compare MPU & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | AEON |
|---|---|---|
| Founded | 1989 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MPU | AEON |
|---|---|---|
| Price | $2.00 | $0.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.82 |
| AVG Volume (30 Days) | 3.0K | ★ 1.2M |
| Earning Date | 12-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.18 |
| 52 Week High | $3.88 | $1.45 |
Technical Indicators
Market Signals| Indicator | MPU | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 42.31 |
| Support Level | $0.62 | $0.23 |
| Resistance Level | $2.97 | $0.33 |
| Average True Range (ATR) | 0.21 | 0.03 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 3.16 | 12.23 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.